source: Nuvilex Press Release
NEW YORK, Feb. 26, 2014 /PRNewswire via COMTEX/ — Nuvilex, Inc. (OTCQB: NVLX) owns exclusive rights to a cancer treatment platform that has successfully completed Phase 2 clinical trials for inoperable pancreatic cancer. Nuvilex also owns rights to the same platform to treat diabetes, and the company also has a medical marijuana subsidiary slated to begin cancer research and development using cannabidiol. With each of the key target markets representing multi-billion-dollar opportunities, Nuvilex offers investors multiple opportunities for success and should trade at a valuation that reflects its current development progress to date.
The company primarily focuses on the advancement of its treatment for advanced, inoperable pancreatic cancer that combines the Cell-in-a-Box technology with the anti-cancer drug ifosfamide. This treatment has completed Phase 1/2 clinical trials. The company, through its subsidiary, Medical Marijuana Sciences, Inc., uses constituents of Cannabis in developing treatments for cancer, particularly those that are difficult to treat.
With the excitement and buzz circulating around this stock in the last few months there is a lot of speculation as to the validity of NVLX. To help investors get a better grasp on NVLX, we have decided to offer a comprehensive research report below.
This comprehensive research report is authored by a Chartered Financial Analyst and includes vital information that every shareholder of NVLX must read. There is no charge for this report. Included in the report you will find recent highlights of NVLX, Overview of the Global Pharmaceuticals Industry, U.S Food and Drug Administration’s (FDA) Approval process for NVLX products, in-depth description of company history, pipeline drugs and current stage, financial position, valuation of company, analyst summary, and price target: http://bit.ly/NVLX-PriceTarget copy and paste may be required
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Osman Ghani, Chartered Financial Analyst. An outsourced research services provider represented by Osman Ghani, Chartered Financial Analyst, has written and reviewed the information in this article or report. BrokerBank Securities, Inc. or Small Cap Street, LLC is not entitled to veto, interfere or alter the articles, documents or report once created and reviewed by the outsourced research provider represented by Osman Ghani, Chartered Financial Analyst. Small Cap Street, LLC is the party responsible for hosting the full analyst report on smallcapstreet.com. Osman Ghani, Chartered Financial Analyst, is the author of research report. BrokerBank Securities, Inc. is the party responsible for issuing this press release. Small Cap Street has compensated Osman Ghani, Chartered Financial Analyst one hundred dollars for the right to disseminate this press release and report. Information in this release is fact checked and produced on a best efforts basis by Osman Ghani, Chartered Financial Analyst.
NOT FINANCIAL ADVICE
BrokerBank Securities, Inc. or Small Cap Street, LLC makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Companies mentioned have not compensated BrokerBank Securities, Inc. Small Cap Street, LLC or Osman Ghani, Chartered Financial Analyst, for the creation or dissemination of this press release. BrokerBank Securities, Inc. or Small Cap Street, LLC. is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by BrokerBank Securities, Inc. or Small Cap Street, LLC. whatsoever for any direct, indirect or consequential loss arising from the use of this document. BrokerBank Securities, Inc. or Small Cap Street, LLC. expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. BrokerBank Securities, Inc. or Small Cap Street, LLC. does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
BrokerBank Securities, Inc. is a member of the Financial Industry Regulatory Authority, CRD number #130116.
SOURCE BrokerBank Securities, Inc.